Farms.com Home   News

Home Enter your keyword Oppy brings lemon plums to North America for 10th year

Oppy is bringing lemon plums to the North American market the first week of February through to mid-March 2023. Limited volumes of the specialty item will arrive on the east coast for a select niche market.

 “Many still call it the volcano plum because it looks like lava is pouring down its sides when the red colouring starts to present itself,” said Oppy sales manager Carl Immenhausen. “Their skin blushes as they ripen, so there is no guesswork about when to eat them.”

Named for their harvest colour, not their flavour, lemon plums are tear-drop shaped, sweet-tasting and juicy.

“It’s a fun and different variety to bring home. Consumers love watching it change colour from yellow to red, and enjoying a unique summertime flavour during the winter months,” shared Immenhausen.

Packed in a high-graphic, one-pound pouch bag, the pack includes a ripening process chart to help educate and excite shoppers to try this unique piece of fruit.

Source : The Grower

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.